Related references
Note: Only part of the references are listed.Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
Elena Zamagni et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
Benjamin A. Derman et al.
BLOOD CANCER JOURNAL (2021)
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD ADVANCES (2020)
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease
Juan-Jose Lahuerta et al.
BLOOD (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment
Noemi Puig et al.
BLOOD (2019)
Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
Evangelos Terpos et al.
HEMASPHERE (2019)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot et al.
BLOOD (2018)
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Juan-Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
J. R. Mills et al.
BLOOD CANCER JOURNAL (2017)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Joaquin Martinez-Lopez et al.
BLOOD (2015)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
Cheng E. Chee et al.
BLOOD (2009)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Share Paper
